Cell Therapy Developers Debate Challenges As Big Pharma Drags Its Feet
This article was originally published in Scrip
Companies developing 'advanced' treatments such as cell therapies face many of the same challenges in getting their innovative products to market, yet the attitudes of management towards the various hurdles differs quite significantly, Scrip found at Alliance for Regenerative Medicine's third annual 'European Advanced Therapies Investor Day' on Nov. 12.
You may also be interested in...
Off-the-shelf placental cell therapy for peripheral artery disease will move from Phase I to registration stage study in US and Europe in early 2017, following “positive feedback” from FDA.
The first cell-based product to be approved in Europe, the TiGenix-developed and Sobi-marketed ChondroCelect, has met an ignominious end with the withdrawal of its marketing authorization. However, TiGenix has entered into an agreement with Takeda for ex-US rights to its next product candidate.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.